ROIV:NASDAQ
Roivant Sciences Ltd
$41.81
arrow_upward
+0.80%(+0.33) 1D
$41.70
arrow_downward
-0.26% (-0.11)bedtimeAfter hours
Closed: Sep 9, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ROIV...
Open
$41.39
High
$42.28
Low
$41.08
Mkt. cap
30.20B
Avg. vol.
7.61M
Volume
0.00
52-wk high
$42.50
52-wk low
$13.40
EPS
-$0.39
Beta
1.12
Shares outstanding
722.32M
No. of employees
721
Open
$41.39
High
$42.28
Low
$41.08
Mkt. cap
30.20B
Avg. vol.
7.61M
Volume
0.00
52-wk high
$42.50
52-wk low
$13.40
EPS
-$0.39
Beta
1.12
Shares outstanding
722.32M
No. of employees
721
News stories
From web sources and news partners
Investing.com Canada
·
11 hours ago
Roivant at Cantor conference: pipeline gains momentum after mosliciguat data
GuruFocus
·
13 hours ago
ROIV Maintains Buy Rating -- Price Target Raised to $55
Investing.com
·
16 hours ago
H.C. Wainwright raises Roivant Sciences price target on trial data
Profile
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
About Roivant Sciences Ltd